drugset / Trial / NCT00003726
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
Phase 1/2
Terminated
1 enrolled
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small cell lung cancer.
Timeline
- Start
- 1998-11
- Primary completion
- 2001-07
- Completion
- 2001-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lepirudin | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Subject | Lepirudin | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | Lepirudin | Protein / enzyme biologic | 20 mg | Subcutaneous |
| Subject | Lepirudin | Protein / enzyme biologic | 25 mg | Subcutaneous |